<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1405-9940</journal-id>
<journal-title><![CDATA[Archivos de cardiología de México]]></journal-title>
<abbrev-journal-title><![CDATA[Arch. Cardiol. Méx.]]></abbrev-journal-title>
<issn>1405-9940</issn>
<publisher>
<publisher-name><![CDATA[Instituto Nacional de Cardiología Ignacio Chávez]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1405-99402020000400480</article-id>
<article-id pub-id-type="doi">10.24875/acm.20000132</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Beneficios y riesgos potenciales de las metas intensivas en el tratamiento de la hipertensión arterial. Revisión sistemática y metaanálisis de ensayos clínicos]]></article-title>
<article-title xml:lang="en"><![CDATA[Benefits and potential risks of intensive goals in the treatment of arterial hypertension. Systematic review and meta-analysis of clinical trials]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[García-Zamora]]></surname>
<given-names><![CDATA[Sebastián]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Rosende]]></surname>
<given-names><![CDATA[Andrés]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Casetta]]></surname>
<given-names><![CDATA[Brunilda]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Grande-Ratti]]></surname>
<given-names><![CDATA[María F.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Carli]]></surname>
<given-names><![CDATA[Natalia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Bertarini]]></surname>
<given-names><![CDATA[Maria F.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Alcuaz]]></surname>
<given-names><![CDATA[María A.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Schoj]]></surname>
<given-names><![CDATA[Verónica]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Ministerio de Salud de la Nación Argentina Dirección Nacional de Promoción de la Salud y Control de Enfermedades Crónicas No Transmisibles ]]></institution>
<addr-line><![CDATA[Buenos Aires ]]></addr-line>
<country>Argentina</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2020</year>
</pub-date>
<volume>90</volume>
<numero>4</numero>
<fpage>480</fpage>
<lpage>489</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S1405-99402020000400480&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S1405-99402020000400480&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S1405-99402020000400480&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Introducción y objetivos: Existe controversia respecto a las metas más adecuadas para el control de la presión arterial. Debido a ello nos propusimos valorar los beneficios y riesgos de adoptar distintos umbrales terapéuticos.  Métodos: Revisión sistemática y metaanálisis de ensayos clínicos de grandes dimensiones a fin de valorar el impacto de las distintas estrategias terapéuticas en la reducción de eventos cardiovasculares y desarrollo de efectos adversos serios.  Resultados: Se incluyeron cuatro ensayos con 29,820 participantes, con edad media de 65±7.9 años. El 42.2% eran mujeres y el 22% eran diabéticos. Globalmente las metas intensivas mostraron una tendencia no significativa hacia la reducción de la mortalidad cardiovascular (riesgo relativo [RR]: 0.89; intervalo de confianza del 95% [IC 95%]: 0.68-1.07; p=0.16) sin impacto en la mortalidad total (p=0.45) y con moderada heterogeneidad entre los ensayos (índice I [I]2: 44 y 59% respectivamente). En cambio, sí redujeron eventos cardiovasculares no fatales (RR: 0.82; IC 95%: 0.70-0.91; p = 0.0003), siendo esto consistente en los ensayos analizados (I2: 0%). Respecto a los efectos adversos, las metas intensivas generaron más consultas a guardia o internaciones (RR: 1.98; IC 95%: 1.59-2.46; p&lt;0.0001; I2: 14%), sin claro incremento en la insuficiencia renal (RR: 1.65; IC95%: 0.94-2.89) y con aumento de las caídas y síncope (RR: 2.39; IC 95%: 1.56-3.67; p&lt;0.0001; I2: 28%).  Conclusión: Metas intensivas de presión arterial reducen eventos cardiovasculares no fatales, sin impacto en la mortalidad, y con un incremento en el riesgo de eventos adversos. Parecería razonable individualizar los objetivos terapéuticos de acuerdo con el riesgo de cada paciente.  Registro: PROSPERO (CRD42020149134).]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Introduction and objectives: There is controversy regarding the most appropriate goals for blood pressure control. We assess the benefits and risks of chossing different therapeutic thresholds.  Methods: We perform a systematic review and meta-analysis of large clinical trials in order to assess the impact of different therapeutic strategies on the reduction of cardiovascular events and the development of serious adverse effects.  Results: Four trials with 29,820 participants were included, with mean age of 65 ± 7.9 years; 42.2% were women and 22% were diabetic. Overall, intensive goals showed a non-significant trend towards reducing cardiovascular mortality (relative risk [RR]: 0.89; 95% confidence interval [CI]: 0.68-1.07; p=0.16) with non-impact in total mortality (p=0.45) and with moderate heterogeneity among the included trials (I index [I]2:44 and 59% respectively). Nevertheless, intensive goals reduce non-fatal cardiovascular events (RR: 0.82; 95% CI: 0.70-0.91; p=0.0003), being consistent in all the analyzed trials (I2: 0%). Regarding adverse effects, intensive goals caused more emergency consultations or hospitalization (RR: 1.98; 95% CI: 1.59-2.46; p&lt;0.0001; I2: 14%), with no clear increase in renal failure (RR: 1.65; 95% CI: 0.94-2.89) but with increase in falls and syncope (RR: 2.39; 95% CI: 1.56-3.67; p&lt;0.0001; I2: 28%).  Conclusion: Intensive blood pressure goals reduce non-fatal cardiovascular events, without reduction in mortality, and with an increase of risk of adverse events. These results suggest that individual goals should be set according to the risk of each patient.  Clinical trial registration: PROSPERO (CRD42020149134).]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Hipertensión arterial]]></kwd>
<kwd lng="es"><![CDATA[Beneficios]]></kwd>
<kwd lng="es"><![CDATA[Riesgos]]></kwd>
<kwd lng="es"><![CDATA[Metas intensivas]]></kwd>
<kwd lng="es"><![CDATA[Metaanálisis]]></kwd>
<kwd lng="en"><![CDATA[Hypertension]]></kwd>
<kwd lng="en"><![CDATA[Benefits]]></kwd>
<kwd lng="en"><![CDATA[Risks]]></kwd>
<kwd lng="en"><![CDATA[Intensive goals]]></kwd>
<kwd lng="en"><![CDATA[Meta-analysis]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kotchen]]></surname>
<given-names><![CDATA[TA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Developing hypertension guidelines:an evolving process]]></article-title>
<source><![CDATA[Am J Hypertens]]></source>
<year>2014</year>
<volume>27</volume>
<page-range>765-72</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. A cooperative study]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>1977</year>
<volume>237</volume>
<page-range>255-61</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[The 1980 report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure]]></article-title>
<source><![CDATA[Arch Intern Med]]></source>
<year>1980</year>
<volume>140</volume>
<page-range>1280-5</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[The 1988 report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure]]></article-title>
<source><![CDATA[Arch Intern Med]]></source>
<year>1988</year>
<volume>148</volume>
<page-range>1023-38</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V)]]></article-title>
<source><![CDATA[Arch Intern Med]]></source>
<year>1993</year>
<volume>153</volume>
<page-range>154-83</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Whelton]]></surname>
<given-names><![CDATA[PK]]></given-names>
</name>
<name>
<surname><![CDATA[Carey]]></surname>
<given-names><![CDATA[RM]]></given-names>
</name>
<name>
<surname><![CDATA[Aronow]]></surname>
<given-names><![CDATA[WS]]></given-names>
</name>
<name>
<surname><![CDATA[Casey Jr]]></surname>
<given-names><![CDATA[DE]]></given-names>
</name>
<name>
<surname><![CDATA[Collins]]></surname>
<given-names><![CDATA[KJ]]></given-names>
</name>
<name>
<surname><![CDATA[Dennison Himmelfarb]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[2017 ACC/AHA/AAPA/ABC/ACPM/AGS/apha/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults:Executive Summary:A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines]]></article-title>
<source><![CDATA[Hypertension]]></source>
<year>2018</year>
<volume>71</volume>
<page-range>1269-324</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wright Jr]]></surname>
<given-names><![CDATA[JT]]></given-names>
</name>
<name>
<surname><![CDATA[Williamson]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
<name>
<surname><![CDATA[Whelton]]></surname>
<given-names><![CDATA[PK]]></given-names>
</name>
<name>
<surname><![CDATA[Snyder]]></surname>
<given-names><![CDATA[JK]]></given-names>
</name>
<name>
<surname><![CDATA[Sink]]></surname>
<given-names><![CDATA[KM]]></given-names>
</name>
<name>
<surname><![CDATA[Rocco]]></surname>
<given-names><![CDATA[MV]]></given-names>
</name>
</person-group>
<collab>SPRINT Research Group</collab>
<article-title xml:lang=""><![CDATA[A Randomized trial of intensive versus standard blood-pressure control]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2015</year>
<volume>373</volume>
<page-range>2103-16</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pierard]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A randomized trial of intensive versus standard blood-pressure control]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2016</year>
<volume>23</volume>
<page-range>2293</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Barrios]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Escobar]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[New targets in arterial hypertension, are they justified?]]></article-title>
<source><![CDATA[Rev Esp Cardiol]]></source>
<year>2018</year>
<volume>71</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>608-11</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vipler]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A randomized trial of intensive versus standard blood-pressure control]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2016</year>
<volume>23</volume>
<page-range>2290-1</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[García-Zamora]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Botto]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Is the evidence provided by the SPRINT trial solid enough to support a systolic blood pressure threshold of 120 mmHg?]]></article-title>
<source><![CDATA[Rev Esp Cardiol]]></source>
<year>2019</year>
<volume>72</volume>
<page-range>520-1</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[McCormick]]></surname>
<given-names><![CDATA[BB]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A randomized trial of intensive versus standard blood-pressure control]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2016</year>
<volume>23</volume>
<page-range>2291-2</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Esler]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[SPRINT, or false start, toward a lower universal treated blood pressure target in hypertension]]></article-title>
<source><![CDATA[Hypertension]]></source>
<year>2016</year>
<volume>67</volume>
<page-range>266-7</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Touyz]]></surname>
<given-names><![CDATA[RM]]></given-names>
</name>
<name>
<surname><![CDATA[Dominiczak]]></surname>
<given-names><![CDATA[AF]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Successes of SPRINT, but still some hurdles to cross]]></article-title>
<source><![CDATA[Hypertension]]></source>
<year>2016</year>
<volume>67</volume>
<page-range>268-9</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schiffrin]]></surname>
<given-names><![CDATA[EL]]></given-names>
</name>
<name>
<surname><![CDATA[Calhoun]]></surname>
<given-names><![CDATA[DA]]></given-names>
</name>
<name>
<surname><![CDATA[Flack]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[SPRINT proves that lower is better for nondiabetic high-risk patients, but at a price]]></article-title>
<source><![CDATA[Am J Hypertens]]></source>
<year>2016</year>
<volume>29</volume>
<page-range>2-4</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Saiz]]></surname>
<given-names><![CDATA[LC]]></given-names>
</name>
<name>
<surname><![CDATA[Gorricho]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Garjón]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Celaya]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[Muruzábal]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Malón]]></surname>
<given-names><![CDATA[MDM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Blood pressure targets for the treatment of people with hypertension and cardiovascular disease]]></article-title>
<source><![CDATA[Cochrane Database Syst Rev]]></source>
<year>2017</year>
<volume>10</volume>
</nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Malhotra]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Nguyen]]></surname>
<given-names><![CDATA[HA]]></given-names>
</name>
<name>
<surname><![CDATA[Benavente]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Mete]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Howard]]></surname>
<given-names><![CDATA[BV]]></given-names>
</name>
<name>
<surname><![CDATA[Mant]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Association between more intensive vs less intensive blood pressure lowering and risk of mortality in chronic kidney disease stages 3 to 5:A systematic review and meta-analysis]]></article-title>
<source><![CDATA[JAMA Intern Med]]></source>
<year>2017</year>
<volume>177</volume>
<page-range>1498-505</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yusuf]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Lonn]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The SPRINT and the HOPE-3 trial in the context of other blood pressure-lowering trials]]></article-title>
<source><![CDATA[JAMA Cardiol]]></source>
<year>2016</year>
<volume>1</volume>
<page-range>857-8</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schünemann]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Bro&#380;ek]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Guyatt]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Oxman]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Manual GRADE para calificar la calidad de la evidencia y la fuerza de la recomendación (1ªed. en español)]]></source>
<year>2017</year>
<publisher-loc><![CDATA[Bogotá, Colombia ]]></publisher-loc>
<publisher-name><![CDATA[Pontificia Universidad Javeriana, Facultad de Medicina, Departamento de Epidemiología y Bioestadística]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Moher]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Liberati]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Tetzlaff]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Altman]]></surname>
<given-names><![CDATA[DG]]></given-names>
</name>
</person-group>
<collab>PRISMA Group</collab>
<article-title xml:lang=""><![CDATA[Preferred reporting items for systematic reviews and meta-analyses:the PRISMA statement]]></article-title>
<source><![CDATA[PloS Med]]></source>
<year>2009</year>
<volume>6</volume>
</nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Higgins]]></surname>
<given-names><![CDATA[JPT]]></given-names>
</name>
<name>
<surname><![CDATA[Green]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cochrane Handbook for Systematic Reviews of Interventions. Version 5.0.2]]></article-title>
<source><![CDATA[The Cochrane Collaboration®]]></source>
<year>2008</year>
</nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Higgins]]></surname>
<given-names><![CDATA[JPT]]></given-names>
</name>
<name>
<surname><![CDATA[Altman]]></surname>
<given-names><![CDATA[DG]]></given-names>
</name>
<name>
<surname><![CDATA[Gøtzsche]]></surname>
<given-names><![CDATA[PC]]></given-names>
</name>
<name>
<surname><![CDATA[Jüni]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Moher]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Oxman]]></surname>
<given-names><![CDATA[AD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The Cochrane Collaboration's tool for assessing risk of bias in randomised trials]]></article-title>
<source><![CDATA[BMJ]]></source>
<year>2011</year>
<volume>343</volume>
</nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sterne]]></surname>
<given-names><![CDATA[JAC]]></given-names>
</name>
<name>
<surname><![CDATA[Savovi&#263;]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Page]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Elbers]]></surname>
<given-names><![CDATA[RG]]></given-names>
</name>
<name>
<surname><![CDATA[Blencowe]]></surname>
<given-names><![CDATA[NS]]></given-names>
</name>
<name>
<surname><![CDATA[Boutron]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Rob 2:a revised tool for assessing risk of bias in randomised trials]]></article-title>
<source><![CDATA[BMJ]]></source>
<year>2019</year>
<volume>366</volume>
</nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dersimonian]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Laird]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Meta-analysis in clinical trials]]></article-title>
<source><![CDATA[Control Clin Trials]]></source>
<year>1986</year>
<volume>7</volume>
<page-range>177-88</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Higgins]]></surname>
<given-names><![CDATA[JPT]]></given-names>
</name>
<name>
<surname><![CDATA[Thompson]]></surname>
<given-names><![CDATA[SG]]></given-names>
</name>
<name>
<surname><![CDATA[Deeks]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Altman]]></surname>
<given-names><![CDATA[DG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Measuring inconsistency in meta-analyses]]></article-title>
<source><![CDATA[BMJ]]></source>
<year>2003</year>
<volume>327</volume>
<page-range>557-60</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cushman]]></surname>
<given-names><![CDATA[WC]]></given-names>
</name>
<name>
<surname><![CDATA[Evans]]></surname>
<given-names><![CDATA[GW]]></given-names>
</name>
<name>
<surname><![CDATA[Byington]]></surname>
<given-names><![CDATA[RP]]></given-names>
</name>
<name>
<surname><![CDATA[Goff Jr]]></surname>
<given-names><![CDATA[DC]]></given-names>
</name>
<name>
<surname><![CDATA[Grimm Jr]]></surname>
<given-names><![CDATA[RH]]></given-names>
</name>
<name>
<surname><![CDATA[Cutler]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
</person-group>
<collab>ACCORD Study Group</collab>
<article-title xml:lang=""><![CDATA[Effects of intensive blood-pressure control in type 2 diabetes mellitus]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2010</year>
<volume>362</volume>
<page-range>1575-85</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lonn]]></surname>
<given-names><![CDATA[EM]]></given-names>
</name>
<name>
<surname><![CDATA[Bosch]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[López-Jaramillo]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Zhu]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Pais]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Blood-pressure lowering in intermediate-risk persons without cardiovascular disease]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2016</year>
<volume>374</volume>
<page-range>2009-20</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Benavente]]></surname>
<given-names><![CDATA[OR]]></given-names>
</name>
<name>
<surname><![CDATA[Coffey]]></surname>
<given-names><![CDATA[CS]]></given-names>
</name>
<name>
<surname><![CDATA[Conwit]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Hart]]></surname>
<given-names><![CDATA[RG]]></given-names>
</name>
<name>
<surname><![CDATA[McClure]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
<name>
<surname><![CDATA[Pearce]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
</person-group>
<collab>SPS3 Study Group</collab>
<article-title xml:lang=""><![CDATA[Blood-pressure targets in patients with recent lacunar stroke:the SPS3 randomised trial]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2013</year>
<volume>382</volume>
<page-range>507-15</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lewington]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Clarke]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Qizilbash]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Peto]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Collins]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality:a meta-analysis of individual data for one million adults in 61 prospective studies]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2002</year>
<volume>360</volume>
<page-range>1903-13</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ettehad]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Emdin]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Kiran]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Anderson]]></surname>
<given-names><![CDATA[SG]]></given-names>
</name>
<name>
<surname><![CDATA[Callender]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Emberson]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Blood pressure lowering for prevention of cardiovascular disease and death:a systematic review and meta-analysis]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2016</year>
<volume>387</volume>
<page-range>957-67</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bangalore]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Toklu]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Gianos]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Schwartzbard]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Weintraub]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Ogedegbe]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Optimal systolic blood pressure target after SPRINT:Insights from a network meta-analysis of randomized trials]]></article-title>
<source><![CDATA[Am J Med]]></source>
<year>2017</year>
<volume>130</volume>
<page-range>707-19</page-range></nlm-citation>
</ref>
<ref id="B32">
<label>32</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Thomopoulos]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Parati]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Zanchetti]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effects of blood pressure lowering on outcome incidence in hypertension:7. Effects of more vs. less intensive blood pressure lowering and different achieved blood pressure levels - updated overview and meta-analyses of randomized trials]]></article-title>
<source><![CDATA[J Hypertens]]></source>
<year>2016</year>
<volume>34</volume>
<page-range>613-22</page-range></nlm-citation>
</ref>
<ref id="B33">
<label>33</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sundström]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Arima]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Jackson]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Turnbull]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Rahimi]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Chalmers]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effects of blood pressure reduction in mild hypertension:a systematic review and meta-analysis]]></article-title>
<source><![CDATA[Ann Intern Med]]></source>
<year>2015</year>
<volume>162</volume>
<page-range>184-91</page-range></nlm-citation>
</ref>
<ref id="B34">
<label>34</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bundy]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Stuchlik]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Bu]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Kelly]]></surname>
<given-names><![CDATA[TN]]></given-names>
</name>
<name>
<surname><![CDATA[Mills]]></surname>
<given-names><![CDATA[KT]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Systolic blood pressure reduction and risk of cardiovascular disease and mortality:A systematic review and network meta-analysis]]></article-title>
<source><![CDATA[JAMA Cardiol]]></source>
<year>2017</year>
<volume>2</volume>
<page-range>775-81</page-range></nlm-citation>
</ref>
<ref id="B35">
<label>35</label><nlm-citation citation-type="journal">
<collab>Blood Pressure Lowering Treatment Trialists'Collaboration</collab>
<article-title xml:lang=""><![CDATA[Blood pressure-lowering treatment based on cardiovascular risk:a meta-analysis of individual patient data]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2014</year>
<volume>384</volume>
<page-range>591-8</page-range></nlm-citation>
</ref>
<ref id="B36">
<label>36</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Thomopoulos]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Parati]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Zanchetti]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effects of blood pressure lowering on outcome incidence in hypertension:3. Effects in patients at different levels of cardiovascular risk--overview and meta-analyses of randomized trials]]></article-title>
<source><![CDATA[J Hypertens]]></source>
<year>2014</year>
<volume>32</volume>
<page-range>2305-14</page-range></nlm-citation>
</ref>
<ref id="B37">
<label>37</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Karmali]]></surname>
<given-names><![CDATA[KN]]></given-names>
</name>
<name>
<surname><![CDATA[Lloyd-Jones]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
<name>
<surname><![CDATA[van der Leeuw]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Goff Jr]]></surname>
<given-names><![CDATA[DC]]></given-names>
</name>
<name>
<surname><![CDATA[Yusuf]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Zanchetti]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Blood pressure-lowering treatment strategies based on cardiovascular risk versus blood pressure:A meta-analysis of individual participant data]]></article-title>
<source><![CDATA[PLoS Med]]></source>
<year>2018</year>
<volume>15</volume>
</nlm-citation>
</ref>
<ref id="B38">
<label>38</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Xie]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Atkins]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Lv]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Bennett]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Neal]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Ninomiya]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effects of intensive blood pressure lowering on cardiovascular and renal outcomes:updated systematic review and meta-analysis]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2016</year>
<volume>387</volume>
<page-range>435-43</page-range></nlm-citation>
</ref>
<ref id="B39">
<label>39</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brunström]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Carlberg]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Association of blood pressure lowering with mortality and cardiovascular disease across blood pressure levels:A systematic review and meta-analysis]]></article-title>
<source><![CDATA[JAMA Intern Med]]></source>
<year>2018</year>
<volume>178</volume>
<page-range>28-36</page-range></nlm-citation>
</ref>
<ref id="B40">
<label>40</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Williams]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Mancia]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Spiering]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Agabiti Rosei]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Azizi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Burnier]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[2018 ESC/ESH Guidelines for the management of arterial hypertension]]></article-title>
<source><![CDATA[Eur Heart J]]></source>
<year>2018</year>
<volume>39</volume>
<numero>33</numero>
<issue>33</issue>
<page-range>3021-104</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
